MARKSANS PHARMA
|
MARKSANS PHARMA Last 5 Year Balance Sheet History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
EQUITY AND LIABILITIES | |||||
Share Capital | ₹45 Cr | ₹45 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr |
Equity - Authorised | ₹55 Cr | ₹55 Cr | ₹55 Cr | ₹55 Cr | ₹55 Cr |
Equity - Issued | ₹45 Cr | ₹45 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr |
Equity Paid Up | ₹45 Cr | ₹45 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr |
Equity Shares Forfeited | - | - | - | - | - |
Adjustments to Equity | - | - | - | - | - |
Preference Capital Paid Up | - | - | - | - | - |
Face Value | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 |
Share Warrants & Outstandings | - | - | ₹93 Cr | - | - |
Total Reserves | ₹2,020 Cr | ₹1,700 Cr | ₹1,068 Cr | ₹846 Cr | ₹595 Cr |
Securities Premium | ₹504 Cr | ₹504 Cr | ₹173 Cr | ₹175 Cr | ₹175 Cr |
Capital Reserves | ₹0.01 Cr | ₹0.01 Cr | ₹0.01 Cr | ₹0.01 Cr | ₹0.01 Cr |
Profit & Loss Account Balance | ₹1,069 Cr | ₹778 Cr | ₹509 Cr | ₹335 Cr | ₹85 Cr |
General Reserves | ₹314 Cr | ₹314 Cr | ₹314 Cr | ₹314 Cr | ₹314 Cr |
Other Reserves | ₹133 Cr | ₹104 Cr | ₹72 Cr | ₹22 Cr | ₹21 Cr |
Reserve excluding Revaluation Reserve | ₹2,020 Cr | ₹1,700 Cr | ₹1,068 Cr | ₹846 Cr | ₹595 Cr |
Revaluation reserve | - | - | - | - | - |
Shareholder's Funds | ₹2,065 Cr | ₹1,745 Cr | ₹1,202 Cr | ₹886 Cr | ₹636 Cr |
Minority Interest | ₹21 Cr | ₹20 Cr | ₹21 Cr | ₹19 Cr | ₹13 Cr |
Long-Term Borrowings | - | - | - | - | - |
Secured Loans | - | - | - | - | - |
Non Convertible Debentures | - | - | - | - | - |
Converible Debentures & Bonds | - | - | - | - | - |
Packing Credit - Bank | - | - | - | - | - |
Inter Corporate & Security Deposit | - | - | - | - | - |
Term Loans - Banks | - | - | - | - | - |
Term Loans - Institutions | - | - | - | - | - |
Other Secured | - | - | - | - | - |
Unsecured Loans | - | - | - | - | - |
Fixed Deposits - Public | - | - | - | - | - |
Loans and advances from subsidiaries | - | - | - | - | - |
Inter Corporate Deposits (Unsecured) | - | - | - | - | - |
Foreign Currency Convertible Notes | - | - | - | - | - |
Long Term Loan in Foreign Currency | - | - | - | - | - |
Loans - Banks | - | - | - | - | - |
Loans - Govt. | - | - | - | - | - |
Loans - Others | - | - | - | - | - |
Other Unsecured Loan | - | - | - | - | - |
Deferred Tax Assets / Liabilities | ₹11 Cr | ₹15 Cr | ₹14 Cr | ₹7.26 Cr | ₹10 Cr |
Deferred Tax Assets | ₹19 Cr | ₹12 Cr | ₹9.16 Cr | ₹2.09 Cr | ₹3.20 Cr |
Deferred Tax Liability | ₹29 Cr | ₹27 Cr | ₹23 Cr | ₹9.35 Cr | ₹13 Cr |
Other Long Term Liabilities | ₹190 Cr | ₹66 Cr | ₹41 Cr | ₹14 Cr | ₹13 Cr |
Long Term Trade Payables | - | - | - | - | - |
Long Term Provisions | ₹4.56 Cr | ₹3.25 Cr | ₹1.86 Cr | ₹2.11 Cr | ₹1.48 Cr |
Total Non-Current Liabilities | ₹205 Cr | ₹84 Cr | ₹57 Cr | ₹24 Cr | ₹24 Cr |
Current Liabilities | - | - | - | - | - |
Trade Payables | ₹268 Cr | ₹231 Cr | ₹200 Cr | ₹169 Cr | ₹110 Cr |
Sundry Creditors | ₹268 Cr | ₹231 Cr | ₹200 Cr | ₹169 Cr | ₹110 Cr |
Acceptances | - | - | - | - | - |
Due to Subsidiaries- Trade Payables | - | - | - | - | - |
Other Current Liabilities | ₹71 Cr | ₹42 Cr | ₹97 Cr | ₹80 Cr | ₹59 Cr |
Bank Overdraft / Short term credit | - | - | - | - | - |
Advances received from customers | ₹2.12 Cr | ₹0.91 Cr | ₹1.74 Cr | ₹0.57 Cr | - |
Interest Accrued But Not Due | - | - | - | - | - |
Share Application Money | - | - | - | - | - |
Current maturity of Debentures & Bonds | - | - | - | - | - |
Current maturity - Others | - | - | - | - | - |
Other Liabilities | ₹68 Cr | ₹41 Cr | ₹95 Cr | ₹79 Cr | ₹59 Cr |
Short Term Borrowings | ₹29 Cr | ₹42 Cr | ₹41 Cr | ₹19 Cr | ₹19 Cr |
Secured ST Loans repayable on Demands | ₹29 Cr | ₹42 Cr | ₹41 Cr | ₹19 Cr | ₹19 Cr |
Working Capital Loans- Sec | ₹29 Cr | ₹42 Cr | ₹36 Cr | ₹19 Cr | ₹19 Cr |
Buyers Credits - Unsec | - | - | - | - | - |
Commercial Borrowings- Unsec | - | - | - | - | - |
Other Unsecured Loans | ₹-29 Cr | ₹-42 Cr | ₹-36 Cr | ₹-19 Cr | ₹-19 Cr |
Short Term Provisions | ₹22 Cr | ₹27 Cr | ₹42 Cr | ₹32 Cr | ₹41 Cr |
Proposed Equity Dividend | - | - | - | - | ₹27 Cr |
Provision for Corporate Dividend Tax | - | - | - | - | - |
Provision for Tax | ₹20 Cr | ₹25 Cr | ₹41 Cr | ₹30 Cr | ₹12 Cr |
Provision for post retirement benefits | - | - | - | - | - |
Preference Dividend | - | - | - | - | - |
Other Provisions | ₹1.96 Cr | ₹1.33 Cr | ₹0.72 Cr | ₹1.86 Cr | ₹1.76 Cr |
Total Current Liabilities | ₹390 Cr | ₹341 Cr | ₹380 Cr | ₹299 Cr | ₹229 Cr |
Total Liabilities | ₹2,681 Cr | ₹2,190 Cr | ₹1,660 Cr | ₹1,228 Cr | ₹902 Cr |
ASSETS | |||||
Gross Block | ₹1,193 Cr | ₹828 Cr | ₹726 Cr | ₹552 Cr | ₹565 Cr |
Less: Accumulated Depreciation | ₹418 Cr | ₹342 Cr | ₹298 Cr | ₹243 Cr | ₹263 Cr |
Less: Impairment of Assets | - | - | - | - | - |
Net Block | ₹776 Cr | ₹486 Cr | ₹428 Cr | ₹309 Cr | ₹303 Cr |
Lease Adjustment A/c | - | - | - | - | - |
Capital Work in Progress | ₹5.38 Cr | ₹7.25 Cr | ₹0.70 Cr | ₹5.60 Cr | - |
Non Current Investments | - | - | - | - | - |
Long Term Investment | - | - | - | - | - |
Quoted | - | - | - | - | - |
Unquoted | - | - | - | - | - |
Long Term Loans & Advances | ₹33 Cr | ₹19 Cr | ₹4.16 Cr | ₹4.16 Cr | ₹5.73 Cr |
Other Non Current Assets | ₹0.17 Cr | - | - | - | - |
Total Non-Current Assets | ₹818 Cr | ₹515 Cr | ₹435 Cr | ₹325 Cr | ₹308 Cr |
Current Assets Loans & Advances | - | - | - | - | - |
Currents Investments | ₹27 Cr | ₹0.54 Cr | ₹0.44 Cr | ₹0.26 Cr | - |
Quoted | - | - | ₹0.44 Cr | ₹0.26 Cr | - |
Unquoted | ₹27 Cr | ₹0.54 Cr | - | - | - |
Inventories | ₹618 Cr | ₹485 Cr | ₹424 Cr | ₹404 Cr | ₹242 Cr |
Raw Materials | ₹262 Cr | ₹203 Cr | ₹151 Cr | ₹118 Cr | ₹92 Cr |
Work-in Progress | ₹25 Cr | ₹20 Cr | ₹11 Cr | ₹15 Cr | ₹16 Cr |
Finished Goods | ₹202 Cr | ₹135 Cr | ₹134 Cr | ₹176 Cr | ₹92 Cr |
Packing Materials | - | - | - | - | - |
Stores  and Spare | - | - | - | - | - |
Other Inventory | ₹129 Cr | ₹127 Cr | ₹128 Cr | ₹96 Cr | ₹43 Cr |
Sundry Debtors | ₹453 Cr | ₹417 Cr | ₹395 Cr | ₹272 Cr | ₹243 Cr |
Debtors more than Six months | ₹6.46 Cr | ₹6.55 Cr | ₹24 Cr | ₹1.97 Cr | - |
Debtors Others | ₹452 Cr | ₹414 Cr | ₹373 Cr | ₹270 Cr | ₹243 Cr |
Cash and Bank | ₹674 Cr | ₹715 Cr | ₹349 Cr | ₹212 Cr | ₹94 Cr |
Cash in hand | ₹0.04 Cr | ₹0.02 Cr | ₹0.03 Cr | ₹0.04 Cr | ₹0.04 Cr |
Balances at Bank | ₹674 Cr | ₹715 Cr | ₹349 Cr | ₹212 Cr | ₹94 Cr |
Other cash and bank balances | - | - | - | - | - |
Other Current Assets | ₹31 Cr | ₹23 Cr | ₹24 Cr | ₹13 Cr | ₹11 Cr |
Interest accrued on Investments | ₹5.74 Cr | ₹2.93 Cr | ₹1.32 Cr | ₹0.10 Cr | - |
Interest accrued on Debentures | - | - | - | - | - |
Deposits with Government | - | - | - | - | - |
Interest accrued and or due on loans | - | - | - | - | - |
Prepaid Expenses | ₹25 Cr | ₹20 Cr | ₹16 Cr | - | - |
Other current_assets | ₹0.11 Cr | - | ₹7.06 Cr | ₹13 Cr | ₹11 Cr |
Short Term Loans and Advances | ₹60 Cr | ₹35 Cr | ₹32 Cr | ₹0.98 Cr | ₹3.40 Cr |
Advances recoverable in cash or in kind | ₹20 Cr | ₹7.48 Cr | ₹4.87 Cr | ₹0.98 Cr | ₹3.40 Cr |
Advance income tax and TDS | ₹4.92 Cr | ₹1.92 Cr | ₹27 Cr | - | - |
Amounts due from directors | - | - | - | - | - |
Due From Subsidiaries | - | - | - | - | - |
Inter corporate deposits | - | - | - | - | - |
Corporate Deposits | - | - | - | - | - |
Other Loans & Advances | ₹35 Cr | ₹26 Cr | - | - | - |
Total Current Assets | ₹1,862 Cr | ₹1,675 Cr | ₹1,225 Cr | ₹903 Cr | ₹594 Cr |
Net Current Assets (Including Current Investments) | ₹1,473 Cr | ₹1,334 Cr | ₹845 Cr | ₹604 Cr | ₹365 Cr |
Miscellaneous Expenses not written off | - | - | - | - | - |
Total Assets | ₹2,681 Cr | ₹2,190 Cr | ₹1,660 Cr | ₹1,228 Cr | ₹902 Cr |
Contingent Liabilities | - | ₹1.45 Cr | ₹1.45 Cr | ₹20 Cr | ₹48 Cr |
Total Debt | ₹29 Cr | ₹42 Cr | ₹41 Cr | ₹19 Cr | ₹19 Cr |
Book Value | 45.57 | 38.51 | 27.10 | 21.66 | 15.54 |
Adjusted Book Value | 45.57 | 38.51 | 27.10 | 21.66 | 15.54 |
Compare Balance Sheet of peers of MARKSANS PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MARKSANS PHARMA | ₹13,505.4 Cr | 1.5% | -14.7% | 89.4% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹450,595.0 Cr | 0.9% | 4.4% | 50% | Stock Analytics | |
DIVIS LABORATORIES | ₹163,089.0 Cr | 4.6% | -1.1% | 55.6% | Stock Analytics | |
CIPLA | ₹124,175.0 Cr | 2.1% | 0.2% | 22.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹114,625.0 Cr | -1.1% | 12.1% | 18.1% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹99,672.5 Cr | 1.8% | 0.9% | 41.3% | Stock Analytics |
MARKSANS PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MARKSANS PHARMA | 1.5% |
-14.7% |
89.4% |
SENSEX | 1.9% |
-0.4% |
10.4% |
You may also like the below Video Courses